Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Breast Cancer
Clinical trial register · United Kingdom · industry-sponsored

Breast Cancer Trials in the UK, 2026

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a UK site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors — the full UK registry across all sponsors is far larger. UK studies may also be registered separately on ISRCTN.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice — all 2863 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 13 Oct 2026, 03:15 UTC
2863
Studies in scope
industry-sponsored, all four open statuses
1385
Recruiting now
open to new participants
542
Lead sponsors
across recruiting studies
Top sites
London 36 Manchester 16 Cardiff 10 Edinburgh 9 Sutton 8
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca10 Hoffmann-La Roche8 Eli Lilly and Company3 Celcuity Inc2 Pfizer2
Site city
London36 Manchester16 Cardiff10 Edinburgh9 Sutton8
All 57 cities
Target enrolment
to

Breast Cancer trials in the UK

46 of 2863 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
UK sites
Start
Recruiting
Zedsen Limited
Observational
220
London
2026-09-30
Recruiting
Hoffmann-La Roche
Phase 2
80
Leicester, London, Manchester
2026-04-07
Recruiting
Hoffmann-La Roche
Phase 2
80
Blackpool, Harlow, Northwood, Middlesex, Oxford
2026-02-18
Recruiting
Novartis Pharmaceuticals
Observational
3,000
London
2025-12-15
Recruiting
XEOS Medical
Observational
850
Coventry
2025-11-19
Recruiting
Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer
NCT07085767Breast Cancer, Locally Advanced Breast Cancer, Metastatic Breast Cancer, ER Positive Breast Cancer
DrugsPalazestrant·Ribociclib·Letrozole
Olema Pharmaceuticals, Inc.
Phase 3
1,000
Brighton, London, Taunton, Guildford, Cardiff
2025-11-03
Recruiting
Relay Therapeutics, Inc.
Phase 3
540
Bath, Cardiff, London, Manchester, Nottingham, Swindon, Truro
2025-08-26
Recruiting
Pfizer
Phase 3
400
Taunton
2025-08-05
Recruiting
Celcuity Inc
Phase 3
1,180
Cambridge, Bathgate, Rickmansworth, Maidstone, Taunton, Cottingham, Glasgow, Leeds
2025-07-24
Recruiting
Hoffmann-La Roche
Phase 3
450
Blackpool, Colchester, Essex, Edinburgh, Harlow, London, Northwood, Oxford, Sheffield
2025-04-09
Active, closed
BicycleTx Limited
Phase 2
66
London
2025-03-03
Recruiting
Merck Sharp & Dohme LLC
Phase 1/2
181
London, Glasgow
2025-02-26
Recruiting
Bristol-Myers Squibb
Phase 1/2
416
London, Glasgow, Birmingham, Newcastle upon Tyne
2025-02-04
Active, closed
Pfizer
Phase 3
1,035
Harlow, Truro, Maidstone, Taunton, Sutton, Coventry, Guildford, London
2025-01-06
Recruiting
Stemline Therapeutics, Inc.
Phase 3
4,220
Truro, Brighton, London, Cheltenham, Northwood, Blackpool, Preston, Livingston
2024-09-27
Active, closed
A Study to Learn About Study Medicine ALTA2618 in Adults With AKT1 E17K-Mutant Solid Tumors
NCT06533059Cancer, Breast Cancer, Endometrial Cancer, Metastatic Cancer
Alterome Therapeutics, Inc.
Phase 1
110
London, Manchester, Newcastle upon Tyne, Sutton
2024-08-22
Recruiting
Hoffmann-La Roche
Phase 4
320
Basingstoke, London, Manchester
2024-04-02
Recruiting
AstraZeneca
Phase 3
625
Cardiff, Chelsea, Leicester, Liverpool, London, Oxford, Surrey, Sutton
2023-11-23
Active, closed
OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer
NCT06016738Breast Cancer, Advanced Breast Cancer, Metastatic Breast Cancer, ER Positive Breast Cancer
DrugsPalazestrant·Exemestane·Anastrozole·Letrozole
Olema Pharmaceuticals, Inc.
Phase 3
510
Leicester, Nottingham, Taunton, Bodelwyddan, London
2023-11-16
Active, closed
AstraZeneca
Phase 3
1,902
Birmingham, Cardiff, Lancaster, London, Northampton, Oxford, Taunton
2023-11-14
Recruiting
Hoffmann-La Roche
Phase 3
420
Basingstoke, Blackpool, Dumfries, Edinburgh, Harlow, Livingston, London, Maidstone
2023-06-07
Recruiting
Magseed Pro(R)/ Sentimag(R) Gen3
NCT05142787Breast Cancer
Endomagnetics Ltd.
Not applicable
224
London, Manchester
2023-03-02
Active, closed
Stemline Therapeutics, Inc.
Phase 1/2
435
Liverpool, London
2023-01-24
Active, closed
Celcuity Inc
Phase 3
701
Bath, Cardiff, London, Manchester, Nottingham, Sutton
2022-12-08
Active, closed
AstraZeneca
Phase 3
1,174
Cambridge, Cardiff, Edinburgh, Greater London, London, Londonderry, Manchester, Newcastle upon Tyne
2022-11-28
Active, closed
AstraZeneca
Phase 3
644
Bristol, Cardiff, Edinburgh, London, Northampton, Nottingham, Warwick
2022-05-16
Recruiting
Eli Lilly and Company
Phase 1
260
London, Sutton
2022-05-11
Active, closed
AstraZeneca
Phase 3
732
Blackpool, Bristol, Cardiff, Colchester, Edinburgh, London, Manchester, Nottingham
2021-10-18
Recruiting
AstraZeneca
Phase 1/2
460
Cambridge, Cardiff, London
2021-10-18
Active, closed
A Study Evaluating the Safety, Pharmacokinetics and Early Efficacy of AVA6000 in Solid Tumours
NCT04969835Salivary Gland Tumor, Urothelial Carcinoma, Ovarian Carcinoma, Breast Cancer
Avacta Life Sciences Ltd
Phase 1
158
Glasgow, Leeds, London, Manchester, Newcastle upon Tyne, Sheffield
2021-07-16
Active, closed
Contrast-Free Magnetic Resonance Imaging for Breast Disease
NCT05006196Breast Cancer, Breast Diseases
Perspectum
Observational
1,030
Oxford
2021-07-06
Active, closed
AstraZeneca
Phase 3
506
Edinburgh
2021-06-22
Active, closed
Hoffmann-La Roche
Phase 3
1,188
Blackpool, Brighton, Cambridge, Cheltenham, London, Manchester, Northwood, Preston
2021-05-04
Active, closed
AstraZeneca
Phase 1/2
702
Cambridge, Manchester, Oxford, Sutton
2020-11-12
Active, closed
AstraZeneca
Phase 3
185
Birmingham, Edinburgh, Glasgow, Hull, London, Manchester, Taunton
2020-08-04
Active, closed
A Phase 1-2 Study of ST101 in Patients With Advanced Solid Tumors
NCT04478279Glioblastoma, Melanoma Stage IV, Breast Cancer, Prostate Cancer
DrugTemozolomide
Sapience Therapeutics
Phase 1/2
125
Edinburgh, Glasgow, Leeds, London
2020-07-01
Active, closed
Daiichi Sankyo
Phase 1
115
London, Manchester, Sutton
2020-02-10
Active, closed
Hoffmann-La Roche
Phase 2/3
325
London, Northwood, Oxford, Plymouth
2020-01-29
Active, closed
Merck Sharp & Dohme LLC
Phase 3
1,240
Bristol, Nottingham, Colchester, London, Solihull, Truro
2018-12-27
Active, closed
Genentech, Inc.
Phase 1
181
London, Suttton
2017-11-24
Active, closed
Eli Lilly and Company
Phase 3
5,637
Truro, Chelmsford, London, Northwood, Blackpool, Preston, Boston, Central Middlesbrough
2017-07-12
Active, closed
Genentech, Inc.
Phase 1
200
Surrey, London
2016-12-13
Active, closed
Hoffmann-La Roche
Phase 2
534
Cambridge, London, Manchester
2015-11-19
Active, closed
Eli Lilly and Company
Phase 3
493
Bebbington, Cambridge, Manchester, Sutton
2014-11-06
Active, closed
AstraZeneca
Phase 3
1,837
Belfast, Birmingham, Bournemouth, Bristol, Cambridge, Cardiff, Dudley, Edinburgh
2014-04-22
Active, closed
Novartis Pharmaceuticals
Phase 1/2
259
Glasgow, Manchester
2013-10-22
Rows per page Showing 1–46 of 46
1
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a UK investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 13 October 2026. https://priyalifescience.com/clinical-trials-uk/condition/breast-cancer

Query this register directly
GET /api/trials?country=uk&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every industry-sponsored study on the registry that lists at least one investigative site in the UK and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 2,863 studies in total at the last sync on 13 Oct 2026, 03:15 UTC. Academic and other non-industry sponsors are out of scope by design. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 46 of those studies listing the condition Breast Cancer.

How many Breast Cancer trials are recruiting in the UK?

19 of the 46 studies on this page are recruiting new participants as of the 13 Oct 2026, 03:15 UTC sync. A further 0 have not yet opened recruitment, 27 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Breast Cancer), 46 studies
PhaseStudiesRecruitingShare
Phase 322847.8%
Phase 1/27315.2%
Phase 16113%
Observational438.7%
Phase 2428.7%
Not applicable112.2%
Phase 2/3102.2%
Phase 4112.2%

Most active sponsors

Lead sponsors with the most studies (Breast Cancer)
Lead sponsorStudiesRecruiting
AstraZeneca102
Hoffmann-La Roche85
Eli Lilly and Company31
Celcuity Inc21
Genentech, Inc.20
Merck Sharp & Dohme LLC21
Novartis Pharmaceuticals21
Olema Pharmaceuticals, Inc.21
Pfizer21
Stemline Therapeutics, Inc.21
Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the UK Pharma Salary Guide, or see the Ireland, EU and USA registers.